Catalent | CTLT - Interest Expense On Debt


Catalent reported $10.51B in Interest Expense on Debt for its fiscal quarter ending in June of 2025.



Interest Expense On Debt Change Date
Agilent USD 27M 1000K Sep/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Bruker USD 20M 4.3M Sep/2025
Centene USD 168M 2M Dec/2025
Charles River Laboratories USD 25.4M 4.56M Sep/2025
Cigna USD 157.92B 157.58B Sep/2025
Danaher USD 55M 12M Dec/2025
Dentsply International USD 23M 1000K Sep/2025
Elevance Health USD 366M 15M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Hologic USD 27.6M 1000K Dec/2025
Humana USD 146M 22M Dec/2025
Illumina USD 25M 0 Sep/2025
Intuitive Surgical USD 19.35B 811.4M Sep/2025
IQVIA Holdings USD 193M 4M Dec/2025
J&J USD 18M 290M Sep/2025
Laboratory Of America USD 56M 1.1M Sep/2025
Lonza CHF 84M 14M Jun/2025
McKesson USD 63M 11M Dec/2025
Merck EUR 126M 47M Sep/2025
Merck USD 412M 85M Dec/2025
Mettler Toledo International USD 17.39M 307K Dec/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Quest Diagnostics USD 69M 2M Sep/2025
Repligen USD 5.41M 60K Sep/2025
Revvity USD 23.51M 742K Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Thermo Fisher Scientific USD 365M 18M Dec/2025
UnitedHealth USD 974M 29M Dec/2025
Waters USD 8.62M 18.02M Dec/2025
West Pharmaceutical Services USD 200K 100K Sep/2025